Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
CRTN @ .93: Q4 ends 12/31. Will they pre-announce Earnings?
Q4 news is due around 2/6/17.
The numbers are likely to be strong.
Imo, they make some news as quick as they can.
Likely a good idea to be holding CRTN when that news hits the wires.
NOTE: A close tomorrow over $1.00 would really kick off the January Effect for this play, putting them on target for being back in Nasdaq compliance @ the close on 1/12/17.
Link:
http://finance.yahoo.com/news/cartesian-reports-substantial-growth-number-170000231.html
GOVX: Action ahead of Fed human AIDS vax milestone payment.
GeoVax market cap is $3.2M
Milestone payment may be bigger than market cap. The total announced in July, 2016 was $7.8M. GOVX got $199,000 at that time to set up the lab for the actual injections which are due to start now.
Zika cash is also on way.
Nov 11, 2016 AIDS vax update:
HIV Vaccine Program -- GeoVax’s most advanced program is a prophylactic vaccine for the Clade B subtype of HIV, the most common form of HIV in North America, Western Europe and Japan. This program has successfully completed Phase 1 and Phase 2a human clinical trials. The next human clinical trial of GeoVax’s preventive HIV vaccine (GOVX-B11) – a Phase 1 trial, designated HVTN 114, will investigate the ability of late boosts to increase the antibody responses elicited by GOVX-B11. HVTN 114 will be conducted by the HIV Vaccine Trials Network (HVTN) with funding from the National Institute of Allergy and Infectious Diseases (NIAID). HVTN has informed GeoVax that it expects this trial to commence in January 2017.
RXII @ .70s: Going to pop on Dr. Frost mania.
The new $10.5M financing killed the stock price.
Few noticed the very big names involved.
Now that BCDA (which I posted here 2 days after it started trading @ .15cents) is topping out, expect the Dr. Frost crowd to load RXII next.
RXII has cash, low float, a pipeline & Dr. Phillip Frost involved.
BCDAs Dr. Frost: His OPK in deal with his new co. RXII ?
RXII fully funded as of last week.
Genius billionaire investor & BCDA owner Dr. Phillp Frost now about to do with RXII what he is doing with BCDA.
RXII is a Nasdaq company with a tiny 6M float and a Dr. Frost company now.
Dr. Frost has brought in other big names on RXII in the last few weeks.
Major play.
RXII news:
http://investors.rxipharma.com/file/Index?KeyFile=37233932
Dr. Frosts OPK in deal with new co. RXII.
RXII fully funded as of last week.
Dr. Phillp Frost now about to do with RXII wwhat he is doing with BCDA.
RXII is a Nasdaq company with a tiny 6M float.
Dr. Frost has brought in other big names on RXII in the last few weeks.
Major play.
RXII news:
http://investors.rxipharma.com/file/Index?KeyFile=37233932
Dr. Frost OTCBB play hot. Nasdaqs RXII @ .70s next.
The Dr. Phil Frost crowd is moving in on RXII @ .70s now.
Tiny 6M float and cash rich.
Watch thems send RXII way higher.
Dr. Frost's BCDA @ 1.05. Frost's RXII @ .70s next.
BCDA up 800% in a few weeks.
RXII a much better play. Loaded with cash & a low float.
The Fr. Frost crowd is finding RXII and other investors will too.
RXII @ .70s.
Great time to bu
Dr. Frost's BCDA @ 1.05. His RXII co. next big play.
BCDA up 800% in a few weeks.
RXII a much better play. Loaded with cash & a low float.
The Fr. Frost crowd is finding RXII and other investors will too.
RXII @ .70s.
Great time to buy.
$CRTN @ .90: Back in Nas compliance in .10 cents.
Low float & regained profitability.
Strong Q4 ending this week.
CEO calls for stronger 2017.
Now, today, about to regain Nasdaq compliance.
$CRTN @ .90: Back in Nas compliance in .10 cents.
Low float & regained profitability.
Strong Q4 ending this week.
CEO calls for stronger 2017.
Now, today, about to regain Nasdaq compliance.
GOVX: AIDS vax & Zika Vax Fed milestone cash due.
Looking just great here
I posted BCDA @ .14. Posting RXII @ .74. Frost plays.
Have to be nuts not to own both plays here.
RXII super cash richm low float & strong pipeline.
Big names besides Dr. Frost just bought in last week.
Website for the new Dr. Phillip Frost company.
http://www.rxipharma.com/
Like BCDA. RXII @ .75: Another new Dr. Frost co. Getting hot.
Cash rich, low float, big pipeline AND a Nasdaq play.
Big.
CRTN @ .80s: Low floater. Only profitable Nasdaq play under $2.50
RXII @ .74. Dr. Frost plays all heating up.
RXII looking great here after $10.5M offering that hammered stock price.
Now sitting on huge cash, low float & strong pipeline.
Website:
http://www.rxipharma.com/
RXII @ .74. Dr. Frost plays all heating up.
RXII looking great here after $10.5M offering that hammered stock price.
Now sitting on huge cash, low float & strong pipeline.
Website:
http://www.rxipharma.com/
GOVX: Twitter link. Excellent instant news link.
Link:
https://twitter.com/geovax_news?lang=en
NOTE: Scroll down for JP. Morgan Conference link
GOVX: " The 50 Most Influential People in Vaccines"
The new Chief Science Officer for GeoVax is Dr. Farshed Guirahkoo.
He has held some of the most important jobs in global vaccine research, including Senior VP for Research at pharma giant Sanofi.
He was recently ranked #22 on the list of the 50 most influential people in vaccines. Ahead of such world renowned vaccine scientists as Dr. Anthony Faucci, the head NIAD.
Most investors have never heard of GOVX or Dr. Guirakoo.
The total market cap for the company is $3.2M dollars, just as the company starts the latest round of injecting humans with a booster shot of AIDS vaccine that has been highly successful in previous trials.
Dr. Farshed Guirahkoo is one of the elite names in science and can write his own ticket with any company in the world. The company he chose is tiny Geovax.
Like him. some investors have done their DD on the GeoVax vaccine platform and see the immense opportunity.
Those folks might not be as smart as Dr. Guirahkoo. They do not have to be. They only need to be smart enough to see a great investment before most other investors.
Google PDF link: NOTE. When cited Dr. Guirahkoo was Chief Science Officer of Hookipa BioTech, founded by the genius Nobel Prize winner, Dr. Rolf Zinkernagel.
The Most Influential People in Vaccines: Vaxcess.com
vaxess.com/wp-content/uploads/2016/.../the-most-influential-people-in-vaccines.pdf
Dr Farshad Guirakhoo is the Chief Scientific Officer of Hookipa Biotech AG, a vaccine biotech start up pioneering a new class of vaccines. DrGuirakhoo.
Past GeoVax human AIDS vax trial results:
https://www.geovax.com/clinical-trials-preventive-hiv-vaccine.html
Milestone payment from this July, 2016 NIH grant is now due:
https://www.geovax.com/news-events/entry/2016/08/02/geovax-awarded-nih-contract-for-up-to-7-8-million-to-manufacture-hiv-vaccine-for-advanced-human-clinical-trials.html
CRTN @ .86. ONLY profitable Nas play under $2.50.
Tiny 6M float.
At HOD right now.
Multi-bagger
CRTN @ .86. ONLY profitable Nas play under $2.50.
Tiny 6M float.
At HOD right now.
Multi-bagger
GOVX: 100% effective Ebola vax. Better than NLNK
NLNK just rocketed higher on news that its Ebola vax is 100% effective.
The bad news is it is restricted from selling the vax in Africa and other poor areas.
It also sold most of the license to Merck.
Another company on the OTCBB, GeoVax, has a 100% effective Ebola vax & has none of those issues.
NOTE: The GeoVax Ebola vax is just one of a number of major vaccines in the pipeline, all with the support of the CDC & NIAH. Just insane that GOVX is @ .06 with a 42M float. Totally crazy.
Ebola Vax:
https://www.geovax.com/news-events/entry/2016/06/01/geovax-ebola-vaccine-protects-non-human-primates-against-lethal-challenge.html
GOVX & NLNK: 100% effective Ebola vax.
NLNK just rocketed higher on news that its Ebola vax is 100% effective.
The bad news is it is restricted from selling the vax in Africa and other poor areas.
It also sold most of the license to Merck.
Another company on the OTCBB, GeoVax, has a 100% effective Ebola vax & has none of those issues.
NOTE: The GeoVax Ebola vax is just one of a number of major vaccines in the pipeline, all with the support of the CDC & NIAH. Just insane that GOVX is @ .06 with a 42M float. Totally crazy.
Ebola Vax:
https://www.geovax.com/news-events/entry/2016/06/01/geovax-ebola-vaccine-protects-non-human-primates-against-lethal-challenge.html
GOVX & NLNK: 100% effective Ebola vax.
NLNK just rocketed higher on news that its Ebola vax is 100% effective.
The bad news is it is restricted from selling the vax in Africa and other poor areas.
It also sold most of the license to Merck.
Another company on the OTCBB, GeoVax, has a 100% effective Ebola vax & has none of those issues.
NOTE: The GeoVax Ebola vax is just one of a number of major vaccines in the pipeline, all with the support of the CDC & NIAH. Just insane that GOVX is @ .06 with a 42M float. Totally crazy.
Ebola Vax:
https://www.geovax.com/news-events/entry/2016/06/01/geovax-ebola-vaccine-protects-non-human-primates-against-lethal-challenge.html
CRTN: ONE stock for 150% gain by 2/6/17.
Buy it.
Put in a GTC @ .$2.30.
Simple as that.
CRTN has tiny float and has now returned to profitability.
Q4 ends in a few days and they will report those numbers roughly around 2/7/17.
Imo, they pre-announce just to goose the stock.
Website:
http://www.cartesian.com/
NOTE: Many CRTN watchers think it is headed back over $5.00. I agree, but am being conservative for this post
CRTN: ONE stock for 150% gain by 2/6/17.
Buy it.
Put in a GTC @ .$2.30.
Simple as that.
CRTN has tiny float and has now returned to profitability.
Q4 ends in a few days and they will report those numbers roughly around 2/7/17.
Imo, they pre-announce just to goose the stock.
Website:
http://www.cartesian.com/
NOTE: Many CRTN watchers think it is headed back over $5.00. I agree, but am being conservative for this post
GOVX: Due AIDS milestone & Zika Fed funding $$.
The former Sr. VP of Sanofi & #22 on the " 50 Most Important People in Vaccine Science" is now the Chief Science Officer of GeoVax since last month.
He took that job just as GOVX announced they were moving on the the human vaccination round for the AIDS drug with their partner the NIAH.
GOVX is due millions in Fed $$ for the AIDS round alone.
No point in beating a dead horse. so i do not post about it much.
No worries however, when the news is posted at any time I will be holding shares. Very cheap shares added in last few weeks as well.
Link:
https://www.geovax.com/component/easyblog/entry/2016/12/14/geovax-announces-appointment-of-farshad-guirakhoo-phd-as-chief-scientific-officer.html?Itemid=101
CRTN @ .80s: Bids building. Thin past $1.00.
$1.00+ puts CRTN back in Nasdaq compliance and sets up January Effect run to the Q4 positive Q and full year numbers for CRTN.
No profitable company on Nasdaq trading below $2.00 to my knowledge and most much higher.
CRTN @ .80s: Bids building. Thin past $1.00.
$1.00+ puts CRTN back in Nasdaq compliance and sets up January Effect run to the Q4 positive Q and full year numbers for CRTN.
No profitable company on Nasdaq trading below $2.00 to my knowledge and most much higher.
RXII @ .70s. Strong early volume
Big cult foloowing for Dr. Phillp Frost companies, CEO of OPK.
RXII has that going for it and the added attraction of being cash rich, low float & strong Phase 3 pipeline.
Dr. Frost nickname as the "Warren Buffet of Bio/Pharma" is well earned.
CTRN @ .86: Strong turnaround confirmation Q4 on way.
Closed @ HOD on better than average volume.
CRTN likely a multibagger by 2/6/17 Q4 Report.
Company business coming back nicely.
Traded in $4.50 to $5.50 range last time it was profitable.
Link:
http://finance.yahoo.com/news/cartesian-reports-substantial-growth-number-170000231.html
CRTN @ .80s: Low float & in profit mode. Turnaround play
Looking very nice indeed as CRTN solidifies its place as the #1 turnaround play of late 2016.
Low float, strong cash and and a positive Q4 coming to an end this week putting CRTN solidly back to profitability.
Expect a Q4 pre-announcement of earnings to keep CRTN rolling solidly over $1.00 and back into Nasdaq compliance.
Just a terrific play & a key January Effect stock.
Was $5.50s last time the company was profitable.
Chart:
http://finviz.com/quote.ashx?t=crtn
CRTN @ .80s. Heads Up. Low float & profitable.
Looking very nice indeed as CRTN solidifies its place as the #1 turnaround play of late 2016.
Low float, strong cash and and a positive Q4 coming to an end this week putting CRTN solidly back to profitability.
Expect a Q4 pre-announcement of earnings to keep CRTN rolling solidly over $1.00 and back into Nasdaq compliance.
Just a terrific play & a key January Effect stock.
Was $5.50s last time the company was profitable.
Chart:
http://finviz.com/quote.ashx?t=crtn
CRTN @ .80s. Heads Up. Breakout formimg ahead of positive Q4 news
Looking very nice indeed as CRTN solidifies its place as the #1 turnaround play of late 2016.
Low float, strong cash and and a positive Q4 coming to an end this week putting CRTN solidly back to profitability.
Expect a Q4 pre-announcement of earnings to keep CRTN rolling solidly over $1.00 and back into Nasdaq compliance.
Just a terrific play & a key January Effect stock.
Was $5.50s last time the company was profitable.
Chart:
http://finviz.com/quote.ashx?t=crtn
RXII @ .70s. Dr. Frost play. Low float/cash rich.
The BCDA crowd that sent his that Dr. Frost play higher on on RXII now.
RXII: Dr. Frost play with BCDA investors catching on.
RXII @ .70s a home run.
Going to get hot just like BCDA
CRTN: Q4: 2/7/2107. Key Jab=nuary Effect play.
Highly likely that CRTN will report solid , in the black, Q4 numbers solidifying the company as a true low float turnaround play.
Roughly six weeks of growing anticipation that unfolds right through the January Effect.
In addition, CRTN inching closer to the $1.00 threshold that will put CRTN back in full Nasdaq compliance as this situation gains momentum.
CRTN looking like an early 2017 home run shot.
Well worth tuning in this week.
Link:
http://www.cartesian.com/
BCDA: Holding since 3rd day of trading.
Hope some of the board members read this post and got in.
550% mover since then.
10/28/16
OPK: Dr. Philip Frost bought 65% of a small private company called BioCardia.
He mergered it with a shell and now the new company, still called BioCardia has $25M in cash and a Phase 3 heart drug.
BCDA quietly began trading on 10.26/16 @ .13.
Just a great deal right now. I bought some in the .13s
LINK:
http://www.biocardia.com
GOVX: Better than NLNK. Vax is 100% effective against Ebola.
GeoVax owns the entire Ebola vax platform.
In addition, has NO restrictions of selling in Africa or other poor areas.
Link:
https://www.geovax.com/news-events/entry/2016/06/01/geovax-ebola-vaccine-protects-non-human-primates-against-lethal-challenge.html
NOTE: NLNK went nuts on Friday based on Ebola results. NLNK is @ $11.00. GOVX maybe should not be that high but it should ne be .06 cents either.
NLNK: GOVX @ .06 has 100% effective Ebola vaccine
GeoVax has programs well underway for AIDS, Ebola, Zika, Yellow Fever, etc.
Totally insane that GOVX trading @ .06....with 42M float.
Emory University, one of the key vaccine developers in the world, owns 10% of GOVX, by the way.
GOVX Ebola link:
https://www.geovax.com/news-events/entry/2016/06/01/geovax-ebola-vaccine-protects-non-human-primates-against-lethal-challenge.html
NOTE : Hope some folks did ok with the NLNK info this morning.
CRTN @ .80s Table pounding time. Multibags by 2/6/17 Q Report.
I have been hitting some solid shots in last few months, including NLNK today.
That being said, CRTN is a great one and the single best stock to own starting off 2017.
The #1 January Effect play..........flat out.